FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MIDDLETON FRED A					2. Issi	2. Issuer Name and Ticker or Trading Symbol CalciMedica, Inc. [CALC]							S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
(Last) (First) (Middle) C/O CALCIMEDICA, INC.						3. Date of Earliest Transaction (Month/Day/Year) 01/23/2024							Officer (give title Other (specify below) below)				
	AST BLVD				4. If A	mendment, Date	d (Month/Day/	- 1	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
(Street) LA JOLI	LA (CA	92037		Rul	Rule 10b5-1(c) Transaction Indication											
(City)	(State)	(Zip)		a C	heck this box to ind ffirmative defense c	icate that onditions	a trans of Rule	saction was made 10b5-1(c). See	t to a contrac n 10.	ntract, instruction or written plan that is intended to satisfy the						
			Table I - N	lon-D	erivative	Securities A	cquire	d, D	isposed of	, or Be	neficially	/ Owned					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Follow Reported	Form: Dir (D) or Ind	Direct In Indirect B : 4) O	Nature of direct eneficial wnership nstr. 4)			
							Code	v	Amount	(A) or (D)	Price	Transaction(s (Instr. 3 and 4			,		
Common	Stock			01/2	23/2024		p (1)		243,356	A	\$3.702	946,744	4]	I V	y anderling enture artners VI, P ⁽²⁾		
Common	Stock			01/2	23/2024		p(1)		144,676	A	\$3.702	727,433	3	I P C II	y anderling fenture artners VI o- nvestment und, L.P. ⁽³⁾		
Common	Stock			01/2	23/2024		P ⁽¹⁾		194,472	A	\$3.702	435,148	8 1	v v	y anderling fentures II, L.P. ⁽⁴⁾		
Common	Stock			01/2	23/2024		p (1)		51,032	A	\$3.702	114,260	0 1		y anderling entures VII Canada), .P. ⁽⁵⁾		
Common	Stock			01/2	23/2024		p (1)		13,184	A	\$3.702	27,609)]	S V A	y anderling entures VII nnex Fund, .P. ⁽⁴⁾		
Common	Stock			01/2	23/2024		p(1)		3,920	A	\$3.702	21,602	:	[V	y anderling fentures Ianagement		
Common	Stock			01/2	23/2024		P ⁽¹⁾		28,744	A	\$3.702	30,292	: 1	I V	y anderling entures Janagement		
Common	Stock											11,714	. Г				
Common	Stock											8,176	1		y Golden riangle fentures, LC ⁽⁶⁾		
			Table I			ecurities Ac						Owned					
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction Date Execution Date, Transaction Date Execution Date, Transaction Date, Transaction Date, Execution Date, Transaction Date, Transaction Date, Execution Date, Transaction Date, Transaction Date, Execution Date, Transaction Date, Execution Date, Transaction Date, Execution Date, Transaction Date Execution Date, Transaction Date, Execution Date, Ex		4. Transaction Code (Instr.	5. Number of Derivative	6. Date E: Expiratio (Month/D	xercis n Date	7. Title and A of Securities		nd Amount ities ng re Security	Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)				

			Table II - Derivative Securities Acquired, Disposed of, or Benefit ativ Owned (e.g., puts, calls, warrants ເຄດຍາຍ Bate Title of Shares										Transaction(s) (Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exercisable Date 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		121,678		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	121,678	\$0.125	121,678	I	By Sanderling Venture Partners VI, LP ⁽³⁾
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		121,678		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	121,678	\$0.125	121,678	I	By Sanderling Venture Partners VI, LP ⁽³⁾
Warrant	\$5.36	01/23/2024		P (1)		72,338		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	72,338	\$0.125	72,338	I	By Sanderling Venture Partners VI Co- Investment Fund, L.P. ⁽³⁾
Warrant	\$7.15	01/23/2024		p (1)		72,338		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	72,338	\$0.125	72,338	I	By Sanderling Venture Partners VI Co- Investment Fund, L.P. ⁽³⁾
Warrant	\$5.36	01/23/2024		P ⁽¹⁾		97,236		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	97,236	\$0.125	97,236	I	By Sanderling Ventures VII, L.P. ⁽⁵⁾
Warrant	\$7.15	01/23/2024		p(1)		97,236		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	97,236	\$0.125	97,236	I	By Sanderling Ventures VII, L.P. ⁽⁵⁾
Warrant	\$5.36	01/23/2024		p (1)		25,516		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	25,516	\$0.125	25,516	I	By Sanderling Ventures VII (Canada), L.P. ⁽⁵⁾
Warrant	\$7.15	01/23/2024		P ⁽¹⁾		25,516		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	25,516	\$0.125	25,516	I	By Sanderling Ventures VII (Canada), L.P. ⁽⁵⁾
Warrant	\$5.36	01/23/2024		p (1)		6,592		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	6,592	\$0.125	6,592	I	By Sanderling Ventures VII Annex Fund, L.P. ⁽⁵⁾
Warrant	\$7.15	01/23/2024		p (1)		6,592		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	6,592	\$0.125	6,592	I	By Sanderling Ventures VII Annex Fund, L.P. ⁽⁵⁾
Warrant	\$5.36	01/23/2024		p (1)		1,960		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	1,960	\$0.125	1,960	I	By Sanderling Ventures Management VI ⁽³⁾
Warrant	\$7.15	01/23/2024		p (1)		1,960		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	1,960	\$0.125	1,960	I	By Sanderling Ventures Management VI ⁽³⁾
Warrant	\$5.36	01/23/2024		p (1)		14,372		01/23/2024 ⁽⁷⁾	12/31/2024 ⁽⁷⁾	Common Stock	14,372	\$0.125	14,372	I	By Sanderling Ventures Management VII ⁽⁵⁾
Warrant	\$7.15	01/23/2024		p (1)		14,372		01/23/2024 ⁽⁸⁾	12/31/2026 ⁽⁸⁾	Common Stock	14,372	\$0.125	14,372	I	By Sanderling Ventures Management VII ⁽⁵⁾

Explanation of Responses:

- 1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

 2. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- 3. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- 4. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII (Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- 5. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- 6. The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

- 7. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
- 8. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

/s/ John Dunn, Attorney-in-Fact 01/25/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.